WBDE: Subsidiary's product has received orphan drug designation in the United States

Zhitong
2025.10.27 08:42

On October 27th, WBDE announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., recently received a recognition letter from the U.S. Food and Drug Administration (FDA), granting orphan drug designation for WP203A for the treatment of pemphigus. Pemphigus is a severe autoimmune blistering disease characterized by widespread loose blisters and erosions on the skin and mucous membranes

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer